2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W127841
    Citric acid-2,4-13C2 121633-50-9 98.00%
    Citric acid-2,4-13C2 is the 13C-labeled Citric acid (HY-N1428). Citric acid is a natural preservative and food tartness enhancer. Citric acid induces apoptosis and cell cycle arrest at G2/M phase and S phase in HaCaT cells. Citric acid cause oxidative damage of the liver by means of the decrease of antioxidative enzyme activities. Citric acid is also an acidulant, emulsifier, sequestrant and buffering agent widely used across many industries.
    Citric acid-2,4-13C2
  • HY-W587977
    3-Hydroxypalmitoylcarnitine 195207-76-2 ≥99.0%
    3-Hydroxypalmitoylcarnitine (3-Hydroxyhexadecanoylcarnitine) is an acylcarnitine. Elevated levels of 3-Hydroxypalmitoylcarnitine are associated with cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM).
    3-Hydroxypalmitoylcarnitine
  • HY-W685943
    Heptaminol 372-66-7 ≥98.0%
    Heptaminol is a fatty amine with pressor properties and a potential antihypotension agent. Heptaminol is also a competitive inhibitor of norepinephrine uptake and an inhibitor of nicotine-induced catecholamine release (IC50: 650 μM). Heptaminol does not inhibit norepinephrine release induced by 59 mM K+ but rather inhibits high-affinity Na+-dependent norepinephrine uptake.
    Heptaminol
  • HY-107372S4
    Uridine triphosphate-15N2 dilithium ≥98.0%
    Uridine triphosphate-15N2 (UTP-15N2 dilithium; Uridine 5'-triphosphate-15N2) dilithium is 15N labeled Uridine triphosphate (HY-107372). Uridine triphosphate (UTP;Uridine 5'-triphosphate) is a nucleotide that regulates the functions of the pancreas in endocrine and exocrine secretion, proliferation, channels, transporters, and intracellular signaling under normal and disease states.
    Uridine triphosphate-15N2 dilithium
  • HY-W004284S
    Heptadecanoic acid-d3 202528-95-8 ≥98.0%
    Heptadecanoic acid-d3 is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis.
    Heptadecanoic acid-d3
  • HY-W011641R
    (±)-Naringenin (Standard) 67604-48-2 98.82%
    (±)-Naringenin (Standard) is the analytical standard of (±)-Naringenin. This product is intended for research and analytical applications. (±)-Naringenin is a naturally-occurring flavonoid. (±)-Naringenin displays vasorelaxant effect on endothelium-denuded vessels via the activation of BKCa channels in myocytes.
    (±)-Naringenin (Standard)
  • HY-12502
    Efonidipine 111011-63-3 99.88%
    Efonidipine(NZ-105) is a dual T-type and L-type calcium channel blocker (CCB).
    Efonidipine
  • HY-50769
    VTP-27999 TFA 1013937-63-7
    VTP-27999 TFA is an alkyl amine Renin inhibitor; VTP-27999 TFA is useful for Hypertension and End-Organ Diseases.
    VTP-27999 TFA
  • HY-76652
    VTP-27999 Hydrochloride 1264191-73-2 98.18%
    VTP-27999 Hcl is an alkyl amine Renin inhibitor; VTP-27999 is useful for Hypertension and End-Organ Diseases.
    VTP-27999 Hydrochloride
  • HY-B1103
    Hydroxyhexamide 3168-01-2 99.60%
    Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agents.
    Hydroxyhexamide
  • HY-B1191
    Nanofin 504-03-0 ≥98.0%
    Nanofin (2,6-Lupetidine) is a neuro-blocking agent with antihypertensive effects, which can be used for the study of mild to moderate hypertension.
    Nanofin
  • HY-N0333
    Yunaconitine 70578-24-4 99.47%
    Yunaconitine(Guayewuanine B) is a highly toxic aconitum alkaloid.
    Yunaconitine
  • HY-N1179
    Tanshinone IIB 17397-93-2 ≥99.0%
    Tanshinone IIB is a major active constituent of the roots of Salvia miltiorrhiza (Danshen) widely used for the research of stroke and coronary heart disease in Asian countries. Tanshinone IIB has a neuroprotective effect via inhibition of apoptosis.
    Tanshinone IIB
  • HY-N7065
    Dihydralazine sulfate 7327-87-9 ≥98.0%
    Dihydralazine sulfate is a vasodilator and an antihypertensive agent.
    Dihydralazine sulfate
  • HY-N7343
    Pregomisin 66280-26-0 99.87%
    Pregomisin is a natural compound isolated from the fruits of Schizandra chinensis Baill. Pregomisin showed PAF antagonistic activity and the IC50 values were 48 μM.
    Pregomisin
  • HY-110315
    Ischemin sodium 99.32%
    Ischemin sodium is a CBP bromodomain inhibitor that inhibits p53 interaction with CBP and transcriptional activity in cells. Ischemin sodium salt inhibits p53-induced p21 activation with an IC50 value of 5 µM. Ischemin sodium salt also prevents apoptosis in ischemic cardiomyocytes. Ischemin sodium salt can be used in the study of cardiovascular diseases (such as myocardial ischemia).
    Ischemin sodium
  • HY-122024
    AZSMO-23 496793-75-0 99.87%
    AZSMO-23 is a potent hERG K+ channel activator. AZSMO-23 activats WT hERG pre-pulse and tail current with EC50 values of 28.6, 11.2 µM, respectively. AZSMO-23 has the potential for the research of long QT syndrome.
    AZSMO-23
  • HY-125641
    AL-34662 210580-75-9 99.19%
    AL-34662 is a selective 5-HT2A receptoragonist (IC50: 0.77 nM and 1.5 nM for rat and human 5-HT2 receptor). AL-34662 is also a weak α-1D adrenergic agonist activity (EC50:0.4 μM). AL-34662 is an ocular hypotensive agent.
    AL-34662
  • HY-126404
    Casein hydrolysate 65072-00-6
    Casein hydrolysate is the hydrolysis product of Casein (HY-125865). Casein hydrolysate reduces the blood pressure, through inhibition of angiotensin-converting enzyme (ACE) and reduction of bradykinin breakdown.
    Casein hydrolysate
  • HY-129738
    I942 868145-09-9 99.38%
    I942 is a first in class, selective non-cyclic nucleotide (NCN) EPAC1 agonist. I942 can attenuate proinflammatory cytokine signalling normally associated with cardiovascular diseases.
    I942
Cat. No. Product Name / Synonyms Application Reactivity